We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Agena Bioscience

Agena Bioscience® empowers research laboratories worldwide to deliver scalable targeted genomic data. Our advanced pl... read more Featured Products: More products

Download Mobile App




Saliva-Based Liquid Biopsy Detects HPV-Caused Head and Neck Cancers

By LabMedica International staff writers
Posted on 27 Sep 2021
A saliva-based liquid biopsy assay was developed that might eventually play an essential role in the detection and management of head and neck cancers caused by high-risk human papillomaviruses.

High-risk human papillomavirus (HR-HPV) infection is a major risk factor of head and neck cancers (HNCs). More...
These cancers constitute 3–5% of all malignancies worldwide and there are approximately 600,000 newly diagnosed cases annually. Patients are usually diagnosed at an advanced stage, since in the early stages, these cancers are difficult to locate with imaging studies or physical examination. Furthermore, the oropharynx is difficult to access, and detection is complicated if these smaller lesions are hidden in the crevices of the tonsils. Importantly, these cancers can metastasize at an early stage, even when the primary cancer is still undetectable in size. Despite the rising prevalence of HPV-driven HNC (HPV-HNC) and closely associated oropharyngeal cancers (OPC), biomarkers for detection, prognostication, and disease monitoring are lacking.

Investigators at Queensland University of Technology (Brisbane, Australia) performed a study to evaluate the potential use of salivary HR-HPV DNA as a biomarker of HPV-HNC. For this study, they employed quantitative real-time PCR and the Agena Bioscience (San Diego, CA, USA) MassARRAY system to analyze saliva samples obtained from 491 patients at the time of first diagnosis of HNC and 10 patients with recurring HNC. An additional group of OPC patients was monitored for a period of up to five years.

Results revealed that of the primary-HNC cohort, 43.2% were positive for salivary HR-HPV DNA, with most having OPC. Salivary HR-HPV DNA was detected in 81.4% of tumor p16–positive OPC patients at diagnosis. Salivary HR-HPV–positive patients had a clear survival advantage over their salivary HR-HPV–negative counterparts. The median event-free survivals were 205 months for HR-HPV–positive patients, compared to 82 months for HR-HPV–negative patients.

“Despite the upsurge in HPV-driven HNC, there are no early detection methods or screening strategies for this cancer type, unlike cervical cancer, which is caused by the same virus. Biomarkers enabling early detection, monitoring, and disease prognostication are warranted to combat the rising incidence of HPV-driven OPC,” said senior author Dr. Chamindie Punyadeera, associate professor of biomedical sciences at Queensland University of Technology. “When the noninvasive nature and convenience of the collection are considered, salivary HR-HPV testing is an ideal mode of screening asymptomatic individuals and the long-term monitoring of HPV-driven HNC patients. Our findings indicate that in the near future, salivary HR-HPV testing will become part of routine clinical management for HPV-driven OPC patients.”

The saliva-based biopsy was described in the July 26, 2021, online edition of The Journal of Molecular Diagnostics.

Related Links:
Queensland University of Technology
Agena Bioscience



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Collection and Transport System
PurSafe Plus®
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.